October 31, 2006
Dr. Ying Luo of Shanghai Genomics presents at the “Drug Development in China – Strategies for
Launching Discovery and Development Activities” in San Francisco, California, USA. The meeting was part of the CHI
Pharmaceutical Strategy Series. His talk focuses on the need to build a balance product pipeline in China. He also
emphasizes the importance of collaboration with international pharmaceutical companies.
|
September 23, 2006
Dr. Ying Luo is invited to speak at the “Shanghai Corporate Forum – Road to Innovation” at the Shanghai Academy of Social Sciences. His speech covers new ideas of how to improve corporate organization, financing, research, and talent recruitment for drug discovery research. He specially emphasizes the impact of East-West culture difference and legal system on novel drug development in China.
|
September 20, 2006
Dr. Ying Luo is invited to join the “China Focus” panel discussion in the BioNetwork 2006 conference in Geneva, Switzerland. Dr. Luo emphasizes the importance of collaboration with western pharmaceutical companies at each stage of the drug discovery and development. He also analyzes how to create a win-win situation in such collaboration. His talk is well received by the audience.
|
September 15, 2006 GNI and Shanghai Genomics announce that scientists identify important regulator and associated signaling cascade in human immunological disorders. The findings of the research are to be published by the Proceedings of the National Academy of Sciences of the United States of America (PNAS), one of the world's most-cited multidisciplinary scientific serials, during the week of September 11, 2006. Dr. Jun Wu, the CSO of GNI and Shanghai Genomics, is the corresponding author of the paper.
|
|
September 11, 2006
Dr. Ying Luo is invited to speak at the UK-Sino Venture Capital Forum at Shanghai. He uses Shanghai Genomics as a case study to analyze how Shanghai Genomics grows with the fast-expanding Chinese economy. He also encourages British venture capital to collaborate with Chinese venture capital to invest in the healthcare industry of Shanghai and eastern China.
|
July 25, 2006 Shanghai Genomics announces the addition of Centocor to a growing list of international research partners. Shanghai Genomics will leverage its protein purification and protein-protein interaction technology to develop new drug targets for Centocor in the fields of oncology and inflammation. This project represents a new milestone in the sourcing business strategy of the Company.
|
|
May 18, 2006
Dr. Ying Luo is invited to give a speech at the Clinical Trial Methods and Models of Asia at Singapore.
The clinical trial experience of Shanghai Genomics receives good comments from the audience.
|
May 17, 2006
Dr. Ying Luo is invited to give a presentation on the drug target discovery program of Shanghai Genomics
in the Post Genomics Summit 2006 held in Beijing. Dr. Luo presents the most recent progress of how to validate kinase
targets and collaborate with other academic research institutes on compound screening. He also emphasizes importance
of long-term investment in R&D for innovative drug discovery.
|
May 14, 2006
Dr. Ying Luo, CEO of Shanghai Genomics, is invited to give a presentation in the conference of Chinese
Biopharmaceutical Association 2006, in Maryland, USA. His topic covers the business model of Shanghai Genomics and how
to cope with various challenges in China. His talk is well received by the audience.
|
April 9-12, 2006
Dr. Jun Yu, Vice President of Shanghai Genomics, attends the BIO2006 in Chicago. In the China
Pavilion， Dr. Yu introduces Shanghai Genomics to enthusiastic visitors and explored new collaborative opportunity.
|
March 6, 2006 The first therapeutic product of Shanghai Genomics, “GuBang” synthetic bone graft, receives approval from the Chinese SFDA for sales in China. This is a new milestone in the history of Shanghai Genomics. The approval demonstrates that Shanghai Genomics has a highly qualified clinical research team. A complete value chain from gene research to production and sales has been formed in Shanghai Genomics.
|
|
January 24, 2006 Shanghai Genomics and Organon, the human healthcare business unit of Akzo Nobel，are to collaborate on a new research project. The collaboration, which will involve biological development work aimed at identification of more selective steroid hormone receptor modulators, will initially last for a period of two years. It extends Organon research interests in China and strengthens Shanghai Genomics’ international credentials. Shanghai Genomics’ integrated drug discovery platform and their expertise in nuclear receptor biology are crucial to the success of this collaboration.
http://www.prweb.com/releases/2006/1/inktomi336684.php
|
|
January 20, 2006
Dr. Ying Luo is invited to attend The China Life Sciences Partnering Forums organized by BURRILL&COMPANY. His panel discussion is focused on the opportunity and challenge of drug discovery in China. He introduces the recent trend of biotech industry in China, and specially analyzes the cost and time factors in drug discovery in China. He also answers questions from enthusiastic audience.
|
|
|
